Celebrating the 20th anniversary of our founding, we continue to take on challenges with our unchanging mission in mind.

SymBio Pharmaceuticals celebrates its 20th anniversary in 2025.
Since our establishment in 2005, we have been challenging Underserved Therapeutic Areas which is difficult for large pharmaceutical companies to enter and has high medical needs. We would like to express our sincere gratitude to our shareholders and all other stakeholders for their understanding of our business.
SymBio Pharmaceuticals is currently in its "second founding phase.
Our business focus has shifted to R&D, and the global development of brincidofovir is progressing well. Each time we receive data from international clinical trials, we are impressed by the high potential of this drug. The drug is attracting attention from world-class research institutions, and we realize that it is a new drug that is eagerly awaited for its launch.
brincidofovir We will continue to make steady progress toward becoming a global specialty pharmaceutical company, with our business in the field of "Therapeutics" at the core of our operations.